` HOOK (HOOKIPA Pharma Inc) vs S&P 500 Comparison - Alpha Spread

HOOK
vs
S&P 500

Over the past 12 months, HOOK has underperformed S&P 500, delivering a return of -83% compared to the S&P 500's +15% growth.

Stocks Performance
HOOK vs S&P 500

Loading
HOOK
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
HOOK vs S&P 500

Loading
HOOK
S&P 500
Difference
www.alphaspread.com

Performance By Year
HOOK vs S&P 500

Loading
HOOK
S&P 500
Add Stock

Competitors Performance
HOOKIPA Pharma Inc vs Peers

S&P 500
HOOK
ABBV
AMGN
GILD
VRTX
Add Stock

HOOKIPA Pharma Inc
Glance View

Market Cap
10m USD
Industry
Biotechnology

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company is headquartered in New York City, New York and currently employs 131 full-time employees. The company went IPO on 2019-04-18. The firm is engaged in developing an immunotherapeutic based on its arenavirus platform, which is designed to target and amplify a T cell and immune response to disease. Its replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its pipeline candidates include HB-200, HB-300, HB-700, HB-101, HB-101 and HBV Therapy. The HB-200 program consists of its arenaviral-based immunotherapies for the treatment of patients with advanced/metastatic cancers caused by 16-positive (HPV16+). Its lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus HPV16+ cancers in a Phase I/II clinical trial. Its non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is for patients awaiting kidney transplantation in Phase II clinical trial.

HOOK Intrinsic Value
4.263 USD
Undervaluation 80%
Intrinsic Value
Price
Back to Top